Stocksigma LogoStocksigma Logo

Mankind Pharma Acquires 70% Stake in Armed Cell Therapeutics for EUR 48Mn

Mankind Pharma approved acquiring a 70% majority stake in Belgium-based Armed Cell Therapeutics B.V. (ACTx) for EUR 48Mn in cash instalments via its wholly

Mankind Pharma Acquires 70% Stake in Armed Cell Therapeutics for EUR 48Mn

Mankind Pharma Ltd 路 Press Release 路 16 Oct 2026, 1:01 am

Mankind Pharma Acquires 70% Stake in Armed Cell Therapeutics for EUR 48Mn Mankind Pharma approved acquiring a 70% majority stake in Belgium-based Armed Cell Therapeutics B.V. (ACTx) for EUR 48Mn in cash instalments via its wholly owned subsidiary, Mankind Pharma (Netherlands) B.V. To fund this, Mankind raised its investment limit in the Netherlands arm by EUR 45Mn to EUR 50Mn on 15th Oct'26. ACTx develops next-generation CAR-T cancer therapies, with lead programs targeting non-Hodgkin lymphoma and small cell lung cancer. The transaction marks Mankind's strategic entry into global, innovation-led oncology cell therapies.

Original exchange filing (PDF)

More announcements from Mankind Pharma Ltd

All Mankind Pharma Ltd announcements